Midomafetamine

Generic Name: Midomafetamine

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅NO_₂

CAS Number: 42542-10-9

Unique Ingredient Identifier: KE1SEN21RM

Background: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication: Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Clinical Trials

A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

Phase 2

Withdrawn

Conditions: Anorexia Nervosa Restricting Type
Binge-Eating Disorder

Interventions: Drug: Midomafetamine
Behavioral: Non-directive therapy
Behavioral: Therapy

First Posted Date: 2020-07-01

Last Posted Date: 2024-10-31

Lead Sponsor: Lykos Therapeutics

Target Recruit Count: 36

Registration Number: NCT04454684

A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

Conditions: Post Traumatic Stress Disorder

First Posted Date: 2020-06-18

Last Posted Date: 2024-11-05

Lead Sponsor: Lykos Therapeutics

Registration Number: NCT04438512

Locations: 🇺🇸
Sunstone Medical, PC, Rockville, Maryland, United States
🇺🇸
Pearl Psychedelic Institute, Waynesville, North Carolina, United States

MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

Phase 2

Active, not recruiting

Conditions: Post Traumatic Stress Disorder
Combat Stress Disorders

Interventions: Drug: 3,4-methylenedioxymethamphetamine

First Posted Date: 2020-02-11

Last Posted Date: 2024-10-07

Lead Sponsor: VA Loma Linda Health Care System

Target Recruit Count: 5

Registration Number: NCT04264026

Locations: 🇺🇸
VA Loma Linda Health Care System, Loma Linda, California, United States

Bristol Imperial MDMA in Alcoholism Study

Phase 1

Conditions: Alcohol Use Disorder

Interventions: Drug: MDMA
Other: Psychotherapy

First Posted Date: 2019-11-12

Last Posted Date: 2019-11-12

Lead Sponsor: Imperial College London

Target Recruit Count: 20

Registration Number: NCT04158778

Locations: 🇬🇧
Study Center: University of Bristol, Bristol, United Kingdom

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Phase 3

Completed

Conditions: Posttraumatic Stress Disorder

Interventions: Behavioral: Therapy
Drug: Midomafetamine
Drug: Placebo

First Posted Date: 2019-09-04

Last Posted Date: 2025-01-14

Lead Sponsor: Lykos Therapeutics

Target Recruit Count: 121

Registration Number: NCT04077437

Locations: 🇺🇸
New School Research, Los Angeles, California, United States
🇺🇸
Aguazul Bluewater, Inc., Boulder, Colorado, United States
🇺🇸
Wholeness Center, Fort Collins, Colorado, United States

and more 11 locations

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

Phase 1

Withdrawn

Conditions: Psychological Effects of Study Drug

Interventions: Drug: Midomafetamine HCl
Behavioral: Therapy

First Posted Date: 2019-08-29

Last Posted Date: 2024-10-31

Lead Sponsor: Lykos Therapeutics

Target Recruit Count: 150

Registration Number: NCT04073433

Stanford Regulating Circuits of the Brain Study - MDMA

Recruiting

Conditions: Healthy

Interventions: Drug: MDMA

First Posted Date: 2019-08-16

Last Posted Date: 2025-02-14

Lead Sponsor: Stanford University

Target Recruit Count: 40

Registration Number: NCT04060108

Locations: 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States

Effects of Drugs on Responses to Brain and Emotional Processes

Early Phase 1

Completed

Conditions: Autism Spectrum Disorder
Healthy

Interventions: Drug: MDMA
Drug: Placebo oral tablet

First Posted Date: 2019-08-12

Last Posted Date: 2024-11-25

Lead Sponsor: University of Chicago

Target Recruit Count: 22

Registration Number: NCT04053036

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

Phase 2

Completed

Conditions: PTSD

Interventions: Drug: Midomafetamine HCl

First Posted Date: 2019-07-23

Last Posted Date: 2025-01-28

Lead Sponsor: MAPS Europe B.V.

Target Recruit Count: 21

Registration Number: NCT04030169

Locations: 🇩🇪
Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin, Berlin, Germany
🇬🇧
The Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
🇳🇱
Stichting Centrum '45/Arq, Oegstgeest, Noord Holand, Netherlands

and more 3 locations

Effect of Stimulant Drugs on Social Perception

Phase 1

Completed

Conditions: Healthy
MDMA ('Ecstasy')

Interventions: Drug: 3,4-Methylenedioxymethamphetamine
Drug: methamphetamine

First Posted Date: 2018-12-31

Last Posted Date: 2024-01-05

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT03790618

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy